» Articles » PMID: 20025047

Juvenile Animal Toxicity Study Designs to Support Pediatric Drug Development

Overview
Date 2009 Dec 22
PMID 20025047
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of juvenile animal toxicity studies of pharmaceuticals is to obtain safety data, including information on the potential for adverse effects on postnatal growth and development. Studies in juvenile animals may assist in identifying postnatal developmental toxicities or other adverse effects that are not adequately assessed in the routine toxicity evaluations and that cannot be safely or adequately measured in pediatric clinical trials. Unlike the traditional reproductive and developmental toxicology studies that have been discussed in the accompanying reports, the design requirements for toxicity studies in juvenile animals are not explicitly defined in regulatory guidance. However, studies in juvenile animals can be useful in providing safety information necessary to enable pediatric clinical trials in pediatric patients or when there are special concerns for toxicities that cannot be safely or adequately measured in clinical trials. These juvenile animal toxicity studies are designed on a case-by-case basis. General design considerations and examples of study designs for assessment of juvenile animal toxicity are discussed.

Citing Articles

Assessing systemic, developmental, and reproductive toxicity and estrogenicity of Korean red ginseng extract G1899 in juvenile Sprague-Dawley Rats.

Kim S, Jeong J, Kim W, Ham O, Quah Y, Jung S J Ginseng Res. 2024; 48(3):333-340.

PMID: 38707647 PMC: 11068984. DOI: 10.1016/j.jgr.2024.01.002.


Transgene-Free Cynomolgus Monkey iPSCs Generated under Chemically Defined Conditions.

Tereshchenko Y, Esiyok N, Garea-Rodriguez E, Repetto D, Behr R, Rodriguez-Polo I Cells. 2024; 13(6.

PMID: 38534402 PMC: 10969578. DOI: 10.3390/cells13060558.


Translating Neurobehavioral Toxicity Across Species From Zebrafish to Rats to Humans: Implications for Risk Assessment.

Vorhees C, Williams M, Hawkey A, Levin E Front Toxicol. 2022; 3:629229.

PMID: 35295117 PMC: 8915800. DOI: 10.3389/ftox.2021.629229.


Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.

Halpern W, Ameri M, Bowman C, Elwell M, Mirsky M, Oliver J Toxicol Pathol. 2016; 44(6):789-809.

PMID: 27235322 PMC: 4979743. DOI: 10.1177/0192623316650052.


Juvenile Toxicology: Relevance and Challenges for Toxicologists and Pathologists.

Remick A, Catlin N, Quist E, Steinbach T, Dixon D Toxicol Pathol. 2015; 43(8):1166-71.

PMID: 26220944 PMC: 4670269. DOI: 10.1177/0192623315595883.